3 Stocks Crushed by the Market This Week презентация

all of them. Here are three that were hammered pretty hard.

1

2

3

Organovo Holdings (NYSEMKT:ONVO)

Source: Yahoo! Finance

weren’t great – miniscule revenue and increasing expenses, it’s unlikely that any observer expected any significant positive developments yet on the financial front
The focus for Organovo continues to be future-oriented, especially with the upcoming unveiling of its 3-D liver assay test

Why Organovo’s stock was 3-D: down, down, down

(NYSEMKT:INO)

Source: Yahoo! Finance

Kim was laying the groundwork for announcing negative news about a phase 2 study of cervical dysplasia vaccine VGX-3100
Inovio responded publicly the next day, calling the article “false and misleading” and “inane conjecture”
The company stated that the data from the phase 2 study remains blinded and plans to report results from the phase 2 study by the end of July

Why the market said “no, no” to Inovio

(NASDAQ:OREX)

Source: Yahoo! Finance

weight loss drug NB32 by three months, with a new PDUFA date of Sept. 11
Why the pushback? The FDA indicated that more time is needed to finalize Orexigen’s post-marketing obligations
The main issue relates to evaluation of cardiovascular outcomes
Orexigen has an ongoing study involving 8,900 patients focusing on these cardiovascular outcomes

Why Orexigen’s share price was slimmed down

reporting positive results for its DNA vaccine
The nod for best chance of rebounding, though, goes to Orexigen
While the FDA’s delay for a decision on NB32 was disappointing, the prospects for approval likely won’t be impacted
For investors who expect that NB32 will achieve greater success than earlier rivals, this week’s pullback could represent a good buying opportunity

Best shot at bouncing back?

?

as the top pick for 2014 in our free report!